Barlic Jana, Zhu Wenjia, Murphy Philip M
Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Immunol. 2009 Jun 15;182(12):7928-36. doi: 10.4049/jimmunol.0804112.
Atherosclerosis is a complex pathologic process in which chemokine-mediated leukocyte accumulation in arterial walls is thought to be an important mechanism of pathogenesis. An interesting exception to this paradigm is the chemokine CXCL16, also known as the scavenger receptor for phosphatidylserine and oxidized low density lipoprotein, which is highly expressed in mouse and human atherosclerotic lesions, yet appears to be atheroprotective. In this study, we address potential mechanisms responsible for this activity. Consistent with its presence in atherosclerotic plaque, we found that atherogenic lipids up-regulated CXCL16 in primary human monocyte-derived macrophages. However, the same lipids down-regulated the CXCL16-targeted protease ADAM10, resulting in preferential expression of CXCL16 as the transmembrane form, not the shed form. Although transmembrane CXCL16 is known to mediate cell-cell adhesion by binding its receptor CXCR6, and atherogenic lipids are known to stimulate macrophage adhesion to coronary artery smooth muscle cells, we found that heterotypic adhesion of these cell types occurred in a CXCL16-independent manner. Instead we found that in macrophages, CXCL16 promoted internalization of both oxidized low density lipoprotein and high density lipoprotein, as well as release of cholesterol. Moreover, CXCL16 deficiency in macrophages interfered with oxidized low density lipoprotein-induced up-regulation of atheroprotective genes: adenosine triphosphate-binding cassette transporter A1 and G1 as well as apolipoprotein E. Thus, our findings support the hypothesis that CXCL16 mediates atheroprotection through its scavenger role in macrophages and not by cell-cell adhesion.
动脉粥样硬化是一种复杂的病理过程,其中趋化因子介导的白细胞在动脉壁中的积聚被认为是发病机制的重要机制。这一模式的一个有趣例外是趋化因子CXCL16,也称为磷脂酰丝氨酸和氧化型低密度脂蛋白的清道夫受体,它在小鼠和人类动脉粥样硬化病变中高度表达,但似乎具有抗动脉粥样硬化作用。在本研究中,我们探讨了导致这种活性的潜在机制。与其在动脉粥样硬化斑块中的存在一致,我们发现致动脉粥样硬化脂质上调了原代人单核细胞衍生巨噬细胞中的CXCL16。然而,相同的脂质下调了CXCL16靶向的蛋白酶ADAM10,导致CXCL16以跨膜形式而非脱落形式优先表达。虽然已知跨膜CXCL16通过结合其受体CXCR6介导细胞间粘附,并且已知致动脉粥样硬化脂质刺激巨噬细胞与冠状动脉平滑肌细胞的粘附,但我们发现这些细胞类型的异型粘附以CXCL16非依赖的方式发生。相反,我们发现在巨噬细胞中,CXCL16促进了氧化型低密度脂蛋白和高密度脂蛋白的内化以及胆固醇的释放。此外,巨噬细胞中CXCL16的缺乏干扰了氧化型低密度脂蛋白诱导的抗动脉粥样硬化基因的上调:三磷酸腺苷结合盒转运体A1和G1以及载脂蛋白E。因此,我们的研究结果支持了这样的假设,即CXCL16通过其在巨噬细胞中的清道夫作用而非细胞间粘附来介导抗动脉粥样硬化保护作用。